![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION
Department of Biopharmaceutical Sciences, University of California, San Francisco, California
Received July 23, 2005; accepted October 27, 2005.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
). ATV undergoes extensive metabolism primarily by cytochrome P450 3A (CYP3A) in the liver to form two active metabolites, ortho-hydroxy atorvastatin and para-hydroxy atorvastatin (Jacobsen et al., 2000). Black et al. (1999) demonstrated that ATV undergoes a similar metabolic pathway in rats, where both parent and metabolite compounds were exclusively excreted in the bile, indicating that hepatic metabolism and biliary excretion are the major routes of elimination.
Drug-drug interactions of ATV are often reported at the level of hepatic phase I or phase II enzymes (Kantola et al., 1998; Lennernas, 2003). Coadministration of ATV and an inhibitor for CYP3A or UDP-glucuronosyltransferase may increase ATV blood concentrations and the risk of rhabdomyolysis (Jacobson, 2004). However, interactions can also occur by inhibition of the relevant hepatic transporters that are located both upstream and downstream of hepatic enzymes. Our group has demonstrated previously, using digoxin and erythromycin as examples, that the ratio of intracellular drug concentrations of parent to metabolite may change when hepatic transporters (both uptake and efflux) are inhibited because the amount of drug available to the enzyme varies with transporter activity (Lam and Benet, 2004; Lau et al., 2004; Sun et al., 2004).
Two carrier-mediated processes govern the sequential transport across the hepatocytes: the sinusoidal (basolateral) uptake from portal/arterial circulation and the canalicular (apical) efflux into the bile. Canalicular efflux transporters P-glycoprotein (P-gp) and multidrug resistance associated protein 2 (MRP2/Mrp2; human/rodent) are the two major ATP-dependent efflux pumps for excretion of drugs into the bile (Keppler and Arias, 1997). At the basolateral membrane of hepatocytes, uptake transporters such as the organic anion transporting polypeptide (OATP/Oatp) are responsible for the influx of bulky amphipathic and hydrophilic compounds (Meier et al., 1997).
ATV has been shown to be a P-gp substrate in various transport studies (Wu et al., 2000; Hochman et al., 2004; Chen et al., 2005). ATV can inhibit MRP2-mediated efflux (Chen et al., 2005), but whether or not it is a substrate of MRP2 had not been confirmed, although other statins, such as pravastatin, have been shown to be substrates of MRP2 (Sasaki et al., 2002; Nezasa et al., 2003). Structurally, ATV consists of a lipophilic region and a more hydrophilic part. Its lipophilicity makes it a good substrate for CYP3A as well as for efflux transporters. In contrast, its hydrophilicity makes it a likely candidate for uptake transporters such as OATP/Oatp. In vitro studies have demonstrated that ATV and other statins, such as cerivastatin, pravastatin, and rosuvastatin, are transported by and are inhibitors of the liver-specific OATP1B1 (previously known as OATP-C or OATP2) (Hsiang et al., 1999; Tokui et al., 1999; Shitara et al., 2003; Simonson et al., 2004; Chen et al., 2005; Kameyama et al., 2005).
As of today, there is no published information on the influence of rat Oatps on the hepatic uptake of ATV and its two hydroxy metabolites. To estimate the contribution of Oatps on the hepatic disposition and metabolism of ATV, rifampicin (RIF) was chosen as a model inhibitor for Oatps since it has been shown to effectively inhibit the OATP/Oatp-mediated uptake of various anionic compounds, including taurocholate, estrone sulfate, as well as the more neutral digoxin, with relatively low Ki values (1-2 µM) (Fattinger et al., 2000; Shitara et al., 2002; Vavricka et al., 2002; Tirona et al., 2003). On the basis of in vitro studies using MRP2-overexpressing cells, Cui et al. (2001) showed that RIF can also inhibit the MRP2-mediated efflux of bromosulfophthalein and leukotriene C4 at high concentrations. Moreover, RIF has also demonstrated an inhibitory effect on P-gp radiolabeling by the photoactivatable P-gp ligand azidopine (Fardel et al., 1995). This is not surprising, because OATP and MRP2 and/or P-gp often work in a concerted manner for drug elimination and share similar substrate and inhibitor specificity, even though the affinity and inhibition potency for uptake and efflux transporters might differ.
In this study, we evaluated the influence of individual hepatic uptake and efflux transporters on the disposition of ATV and its metabolites and characterized the effects of RIF on the hepatic uptake and efflux, as well as metabolism of ATV, using cellular systems and rat microsomes. To directly observe how the dynamic interplay between transporters and enzymes contributes to alterations in ATV pharmacokinetics, the isolated perfused rat liver (IPRL) system was used.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Transient Transfection and Uptake Transport Assays. All OATP/Oatp expression plasmids were sequence-verified, and when they were expressed in cells, they were shown to be transport-competent toward prototypical substrates (estrone sulfate, digoxin, cholecystokinin) (data not shown). HEK293 cells were cultured in Eagle's minimal essential medium with Eagle's balanced salt solution and l-glutamine plus 10% heat-inactivated fetal bovine serum (FBS), nonessential amino acids, sodium pyruvate, streptomycin, and penicillin. Cells were seeded into poly-D-lysine-coated 12-well plates at a density of 0.5 x 106 cells/well 1 day prior to transient transfection with OATP1B1, Oatp1a1, Oatp1a4, and Oatp1b2 plasmids or pEF/V5-His vector control (Invitrogen) using the Lipofectamine 2000 transfection system according to the manufacturer's directions. Culture medium was replaced 24 h before the uptake studies with the same medium containing 10 mM sodium butyrate to induce the expression of transporters. Before initiation of the uptake study, cells were washed once with phosphate-buffered saline (PBS) prewarmed at 37°C. The uptake study was initiated by adding 0.5 ml of Opti-MEM I buffer (Invitrogen) containing substrates and incubating at 37°C for 3 min. Preliminary experiments had shown that the uptake rate was linear over this time period (data not shown). For the inhibition studies, inhibitors and substrates were added simultaneously. At the designated times, buffer was removed to terminate the reaction and the cells were washed three times with ice-cold PBS. The homogenate was centrifuged for 5 min at 13,000g, and the resulting supernatant was analyzed by LC/MS-MS. The protein concentrations in cell experiments were determined by the method of Lowry et al. (1951) using bovine serum albumin as a standard.
Preparation of Cell Culture Monolayers and Transport Studies. MII-cMOAT and MII cells were cultured at 37°C and humidified 5% CO2 atmosphere in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, and 100 U/ml streptomycin. M-MDR1 cells were cultured in the same medium containing 80 mg/ml colchicine for selected growth of transfected cells (Pastan et al., 1988). Cells grown to confluence in culture flasks were harvested and seeded into Transwell inserts in six-well plates at a density of 
106 cells/insert. Studies were conducted 5 to 6 days postseeding for the two cell lines. Medium was changed once every 2 days and 24 h before the experiment.
The transport experiments were adapted with modifications from Flanagan et al. (2002) and Cummins et al. (2004). In brief, cell monolayers were preincubated in transport buffer (Hanks' balanced salt solution containing 25 mM HEPES and 1% FBS, pH 7.4) for 20 min at 37°C. Transepithelial electrical resistance was measured in each well using a Millicell ERS voltohmmeter (Millipore Corporation, Bedford, MA) to assess the integrity of monolayers. The average transepithelial electrical resistance values obtained from MII, MII-cMOAT, and M-MDR1 cells were 170 ± 15 
· cm2 (n = 12), 160 ± 10 · cm2 (n = 12), and 1780 ± 20 · cm2 (n = 12), respectively. For measuring drug secretion (B)asolateral 
(A)pical, 2.5 ml of transport buffer containing ATV (5 µM) was put into the B side and 1.5 ml of buffer was put into the A side. At the selected times (1, 2, and 3 h), 150-µl samples were taken from the A side and replaced with fresh buffer. For measuring drug absorption (A B), the drug solution was put into the A side and samples were taken from the B side. For inhibition studies, the inhibitor RIF (50 µM) or GG918 (0.5 µM) was put into both the A and B sides. During the studies, the cells were incubated in a shaking incubator (Boekel Scientific, Feasterville, PA). After the last time point (3 h), the apical solutions were removed by suction and each filter was dipped twice in ice-cold PBS. Intracellular measurements of ATV were obtained by solubilizing the cells on each culture insert with 0.4 ml of ice-cold MeOH/H2O [7/3 (v/v)] and sonicating for 10 min. The homogenate was centrifuged for 5 min at 13,000g, and the resulting supernatant was analyzed by LC/MS-MS.
Metabolism by Rat Liver Microsomes. Rat liver microsomes were isolated and incubated as described previously by our laboratory (Jacobsen et al., 2000). In brief, microsomal proteins (0.75 mg/ml), 0.1 M phosphate buffer, pH 7.4, and ATV (in methanol, final concentration 1 µM) were preincubated for 5 min. NADPH (1 mM) was added to start the reaction at 37°C. To assess the effects of RIF on ATV metabolism, RIF (in dimethyl sulfoxide, final concentration 10-250 µM) was added to the liver microsomal preparations. The reaction was stopped by protein precipitation by the addition of an equal volume of ice-cold acetonitrile containing the internal standard fluvastatin (0.5 µM). The supernatants were stored at -80°C for LC/MS-MS measurement.
Surgery and Perfusion of Isolated Rat Livers. Male Sprague-Dawley rats (300-400 g; Bantin and Kingman, San Leandro, CA) were anesthetized with ketamine/xylazine (80 mg; 12 mg/ml) before surgery. The hepatic portal vein and superior vena cava were cannulated after the approval of protocols by the Committee on Animal Research, University of California (San Francisco, CA). The livers were isolated for perfusion ex situ using standard techniques as described previously by our laboratory (Wu and Benet, 2003; Lau et al., 2004). In brief, recirculating perfusion was performed at 37°C from a reservoir containing 110 ml of perfusate composed of Krebs-Henseleit buffer, pH 7.4, supplemented with sodium taurocholate (220 nmol/min), 1% bovine serum albumin, and glucose (10 mM), through the liver via a catheter inserted in the portal vein. The perfusate in the reservoir was oxygenated directly using carbogen (95% O2/5% CO2) and stirred continuously. Measures of liver viability included oxygen consumption, portal vein pressure (20-30 mm Hg), pH 7.35-7.45, and metabolic capability. Livers were allowed to stabilize for 20 min. RIF was added to the reservoir 5 min before ATV addition. Perfusate samples (0.5 ml) were collected immediately (0 min) and at 3, 5, 10, 15, 20, 30, 45, and 60 min after the addition of ATV, and accumulative bile samples were collected for up to 60 min. At the end of experiment, the liver was removed, blotted dry, and weighed. An aliquot of liver was homogenized with ice-cold PBS in a 1:2 ratio and maintained frozen at -80°C before analysis. To examine the effects of RIF on ATV hepatic disposition, 20 rats were divided equally into four groups, and each group was perfused with a bolus dose of ATV to yield an initial perfusate concentration of 1 µM. Whereas one group served as the control, the other three groups served as treatment groups for inhibition studies, with three different final perfusate concentrations of RIF (5, 10, and 50 µM). Samples were prepared by liquid-liquid extraction as described previously (Lau et al., 2004). In brief, 3 ml of methyl tertiary butyl ether with internal standard fluvastatin (0.5 µM) was added to each liver, bile, and perfusate sample. After centrifugation, separation of the organic layer in a methanol dry ice bath, and evaporation of the organic layer under nitrogen gas, the dried solutes were reconstituted with methanol for analysis by LC/MS-MS.
LC/MS-MS Measurement of ATV and Metabolites. A Micro-mass Quattro Ultima instrument (Waters, Milford, MA) with electrospray-positive ionization was used. The multiple reaction monitor was set at 559.6-440.8 m/z for ATV, 575.2-440.5 m/z for 2-OH ATV and 4-OH ATV, and 412.3-265.9 m/z for the internal standard fluvastatin. The cone voltage and collision energy were set at 30 V and 20 eV, respectively. The analytical Agilent XDB C18 column (4.6 x 50 mm, 5-µm particle size; Agilent Technologies, Palo Alto, CA) was used. The mobile phase consisted of 46% acetonitrile containing 0.05% acetic acid and 5 mM ammonium acetate. Five-microliter aliquots were injected, and the flow rate was set at 1.0 ml/min with a one-fourth split into the mass system.
HPLC Measurement of RIF. The HPLC method for analyzing RIF was described previously (Lau et al., 2004). In brief, liver samples were analyzed on a HP1100 HPLC system (Hewlett Packard, Palo Alto, CA). RIF was resolved on a Microsorb-MV C8 analytical column (4.6 x 250 mm, 4-µm particle size; Varian, Inc., Walnut Creek, CA). The mobile phase was composed of 0.05 M potassium dihydrogen phosphate/acetonitrile [55/45(v/v)] at a flow rate of 1 ml/min. The UV absorbance was monitored at a wavelength of 340 nm.
Data Analysis. The kinetics parameters for the uptake of ATV in the transporter-expressing HEK293 cells were obtained by using the following equation,
 | (1) |
where v0 is initial uptake rate, S is the substrate concentration, Km is the Michaelis constant, Vmax is the maximal uptake rate, and Pdif is the nonsaturable uptake clearance. The above equation was fitted to the data, using a nonlinear least-squares method by SigmaPlot (Version 5.0; SPSS Inc., Chicago, IL). To obtain the IC50 value of RIF inhibition on ATV uptake, the data were fitted using WinNonlin (Scientific Consulting, Inc., Apex, NC). For transport studies, the permeability (Papp) values were calculated as follows where the rate of transport was measured from the flux of drug across the cells.
 | (2) |
For the IPRL studies, values for area under the concentration time curve (AUC) were calculated using the linear trapezoidal method. Biliary clearance (CLb) was the quotient of the cumulative biliary amount of ATV and the AUC of ATV. Student's t test was used to analyze differences between two groups. Analysis of variance was used to analyze differences among more than two groups, and the significance of difference between two means in these groups was evaluated using Tukey's post hoc test. The p value for statistical significance was set at <0.05.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
|
|
|
|
Transport Studies of ATV in MII, MII-cMOAT, and M-MDR1 Cell Systems. A significantly (p < 0.01) higher B A transport of ATV across MII-cMOAT cells (Papp = 2.65 x 10-6 cm s-1) than across MII cells (Papp = 1.52 x 10-6 cm s-1) was observed resulting in a net flux ratio (B A/A B) ratio of 3.03 ± 0.43 for MII-cMOAT cells (Table 1). In MII cells, the net flux ratio was also higher than 1. This could be explained by the presence of endogenous canine P-gp as well as MRP2 present in the cells, as previously shown in our laboratory (Flanagan et al., 2002) by Western blot, which would be expected to generate partial transepithelial transport of ATV. With the addition of RIF (50 µM), the B A permeability of ATV across MII-cMOAT was significantly reduced by 50%, resulting in a 3-fold decrease in the net flux ratio (Table 1). The intracellular ATV accumulation also significantly increased (p < 0.05) compared with the MII-cMOAT control (Table 1). In MII cells, the B to A transport of ATV was also decreased by RIF because of the presence of modest expression levels of endogenous MRP2 (Flanagan et al., 2002). RIF demonstrated no inhibitory effect on P-gp at 50 µM using P-gp-overexpressing M-MDR1 cells (Fig. 6A); however, GG918, a relatively specific inhibitor for P-gp (Cummins et al., 2004), at 0.5 µM completely eliminated the bidirectional difference in transport (Fig. 6B).
|
|
Metabolic Studies of ATV by Rat Microsomes. The inhibitory effects of RIF (0-250 µM) on the metabolism of ATV were examined (Table 2). RIF did not alter the metabolic formation of 2-OH ATV up to a concentration of 25 µM and reduced it to 57% of the control value at 250 µM. RIF did not significantly affect the formation of 4-OH ATV at concentrations lower than 100 µM.
|
IPRL Studies of ATV. Figure 7A illustrates the disposition of ATV in perfusate over time in the absence (control) and presence of various concentrations of RIF (5, 10, and 50 µM). In all RIF-treated groups, ATV concentrations at all of the sampling times were elevated (Fig. 7A). The AUC of ATV over the 1-h sampling period was significantly increased by 56, 108, and 151% for 5, 10, and 50 µM RIF-treated groups, respectively, as shown in Table 3. The concentrations of 2-OH ATV and 4-OH ATV were detectable 15 min after the start of perfusion and increased steadily up to 60 min (Fig. 7, B and C), indicating that hepatic enzymatic activity of CYP3A was functional throughout the perfusion period. The observed increase in metabolites perfusate concentrations without a concomitant decrease in ATV perfusate concentrations after the rapid initial distribution phase might be due to significant evaporation from perfusate or cis-inhibition of ATV uptake by the metabolites accumulated in the perfusate. Both metabolites could inhibit ATV uptake at the same or 10-fold higher molar concentration of ATV in cellular uptake studies (Fig. 5).
|
|
The AUC of both hydroxy metabolites were increased by 20% for 5 µM RIF, 80% for 10 µM RIF (p < 0.01), and 100% by 50 µM RIF (p < 0.001) treated groups (Table 3). The ratio of the sum of the metabolite AUC to parent AUC (OH ATV AUC/ATV AUC) was comparable for all RIF-treated groups and control group.
The amounts of ATV and metabolites recovered in various matrices from IPRL studies in the absence and presence of RIF are presented in Table 4. The amounts of RIF recovered in the liver homogenate increased linearly with the RIF dose administered (y = 2.49x - 3.71; r2 = 0.998). The majority of the dose recovered was present in the liver homogenate as ATV at the end of the experiment (1 h). ATV amount was significantly decreased in 5 µM RIF-treated livers and slightly decreased in 10 µM RIF-treated livers. In 50 µM RIF-treated livers, however, there was an increase in ATV amount, although not significant. Liver retention of metabolites was reduced, with a significant decrease of 50% for total metabolites (sum of 2-OH ATV and 4-OH ATV) in all RIF-treated groups. The ratios of total metabolites to parent retention in liver were calculated for all groups (Table 3). There was a gradual decrease of the ratios with increasing RIF concentration (19, 35, and 60% decrease for 5, 10, and 50 µM RIF, respectively). However, only the 50 µM RIF-treated group exhibited a significant decrease.
|
RIF exhibited a concentration-dependent inhibitory effect on the biliary excretion of ATV and metabolites, in which the cumulative amounts were significantly reduced in the 10 and 50 µM RIF-treated groups (Table 4; Fig. 8, A and B). The biliary clearance of ATV significantly decreased 51, 84, and 95% by 5, 10, and 50 µM RIF, respectively. The ratios of amounts of ATV in bile/liver were statistically unchanged for 5 and 10 µM RIF-treated groups but significantly decreased 88% by 50 µM RIF (Table 3). The bile/liver ratio for total OH ATV was not significantly changed between groups. Mass balance calculations (ATV, 2-OH ATV, and 4-OH ATV in perfusate, liver, and bile) show no statistical significant differences among the four studies (79.3 ± 8.4% for control, 70.0 ± 6.5% with 5 µM RIF, 79.4 ± 8.2% with 10 µM RIF, and 93.1 ± 13.9% with 50 µM RIF). However, for the 5 and 10 µM RIF treatment groups where we expect no effect on the enzymatic process, the increase in perfusate drug and metabolite amounts seems to be balanced by the decreased amounts in the liver so that the total percentage of metabolites (perfusate, liver plus bile) is essentially the same as that for control (28.7% for control, 26.4% for 5 µM RIF, and 30.8% for 10 µM RIF) (Table 4). This unexpected finding differs from our previous digoxin reports (Lam and Benet, 2004; Lau et al., 2004).
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Our uptake study results demonstrate that ATV is a substrate of OATP1B1, Oatp1a4, and Oatp1b2 (Fig. 1), the rat ortholog of OATP1B1 (Kakyo et al., 1999; Cattori et al., 2001). RIF is capable of inhibiting ATV uptake mediated by both Oatps in a concentration-dependent manner (Fig. 3). Recently, it has been demonstrated that RIF is a substrate of Oatp1b2 (Tirona et al., 2003), which is liver-specific and exhibits the highest amino acid sequence identity with OATP1B1 (Cattori et al., 2001). It is likely that RIF competitively reduces the sinusoidal uptake of ATV via this transporter as well as the more well studied Oatp1a4 (Fattinger et al., 2000; Shitara et al., 2002).
Similar to P-gp, MRP2 is an efflux transporter expressed at high levels in the canalicular domains of hepatocytes (Evers et al., 1998). Transport studies were used as a tool to evaluate the influence of MRP2 on drug export, because the cellular B A transport mimics the orientation of apical efflux transporters in the liver. The results generated from the MII-cMOAT cells indicate that ATV is a cosubstrate of both P-gp (Fig. 6B) and MRP2 (Table 1), with a net flux ratio of 3 using the MII-cMOAT cells, a value that reflects the leaky nature of this cell line. Incubation with 50 µM RIF results in decreased Papp (B A), a change in the flux ratio to approximate unity, along with a significant increase in intracellular ATV accumulation (Table 1). These results support the report of Cui et al. (2001) in that RIF is capable of inhibiting MRP2 as well as OATP.
The working concentration of ATV was carefully chosen at 1 µM in the IPRL study, which is well below the Km values (23.8 and 19.8 µM for 2-OH ATV and 4-OH ATV formation, respectively) obtained from microsomal studies (data not shown) and uptake studies (Fig. 2, A and B), to prevent saturation of both enzyme and Oatp transporters. As expected, RIF significantly increased the AUC of ATV in the IPRL studies at all of the three tested concentrations (5, 10, and 50 µM).
The influence of Oatps on hepatic transport of the two ATV active hydroxy metabolites has not been reported previously. In the present IPRL studies, we observed an increase in AUC for both metabolites by RIF in a concentration-dependent manner. This phenomenon is consistent with the uptake study in which both metabolites are substrates of Oatp1b2 and that RIF significantly inhibits their uptake (Fig. 4). Our previous digoxin IPRL study (Lau et al., 2004) showed that inhibition of digoxin hepatic uptake led to an increase in parent drug AUC but a decrease in metabolite AUC; hence, a decrease in metabolite/parent AUC ratio was observed. We suspect that this decrease in ratio is a result of the metabolite not being a substrate, at least not as good a substrate for the uptake transporter as the parent drug. In the present study, the metabolite/parent AUC ratios remain statistically unchanged, indicating that the disposition of the two ATV metabolites were inhibited by RIF to a similar extent as the parent ATV.
Overlap in inhibitor selectivity for enzyme versus transporter makes it difficult to differentiate the roles of uptake transporter and enzyme in drug disposition, because inhibition of either can lead to an increase in drug exposure. Therefore, we examined the inhibitory effect of RIF on CYP-mediated metabolism of ATV in microsome. RIF seems to have only a moderate effect on metabolism, showing inhibition only at higher concentrations (
50 µM) (Table 2). RIF liver concentrations reached values of 11.2 and 18.4 µM for the 5 and 10 µM RIF doses, respectively (Table 3), concentrations well below 50 µM. Therefore, less ATV and metabolites were detected in liver tissues for 5 and 10 µM RIF doses (Table 4), indicating that RIF has an inhibitory effect on uptake but no effect on metabolism at concentrations less than 50 µM in the liver. Although not statistically significant, the metabolites/parent liver ratios between the control and the 5 and 10 µM RIF treatment groups seem to decrease gradually with increasing RIF concentration (Table 3). Because the metabolites seem to be more susceptible than the parent to Oatp-mediated uptake, more metabolites would stay in the perfusate as opposed to the liver (Fig. 7, B and C); hence, the extent of decrease in liver retention for metabolites would be greater than that for parent drug.
A greater and significant decrease in the metabolite/parent liver ratio was observed for the 50 µM RIF treatment group (Table 3). Here, RIF liver concentration reached a value of 120 µM, a concentration high enough to inhibit the formation of both metabolites (Table 2). However, the increase in ATV retention in liver cannot be attributed to enzymatic inhibition only. Note that the bile/liver amount ratio for ATV was relatively constant across control and the 5 and 10 µM RIF treatment groups (Table 3), suggesting that the change of parent drug and metabolites in bile is reflective of what is observed in the liver. However, the ratio was significantly decreased in the 50 µM RIF treatment group (Table 3), suggesting that apical transporters mediating the efflux of ATV might be inhibited at this concentration. Determining whether the metabolites are substrates of P-gp and Mrp2 is the subject of continuing studies in our laboratory. However, it is likely that increased ATV retention in liver is partially caused by Mrp2 inhibition based on our present transport study results (Table 1). We also tested the potential for 50 µM RIF to inhibit P-gp, using P-gp overexpressing cells. No inhibition of transport activity could be detected (Fig. 6A). Obviously, to unambiguously characterize the pharmacokinetics of ATV, the contributions of other transporters such as breast cancer resistance protein (Bcrp) and bile salt export pump (Bsep) at the canalicular border and Mrp3 and sodium/taurocholate-cotransporting polypeptide (Ntcp) on the basolateral side should be further examined.
It has been suggested that the concerted action of uptake and efflux transporters govern the movement of drugs across hepatocytes and that combined inhibition of both types of transporters may account for the observed drug interactions in vivo (Cvetkovic et al., 1999; Cui et al., 2001; Sasaki et al., 2004). However, it is essential to recognize that uptake and efflux transporters may exert opposing effects on liver drug concentrations of both parent drug and metabolites. Recent studies from our laboratory have shown that both decreased and increased metabolism of digoxin were observed when Oatp1a4 and P-gp were inhibited, respectively (Lam and Benet, 2004; Lau et al., 2004). When efflux is blocked, more drug is available to be metabolized by the enzyme, whereas less drug can access the enzyme when uptake is inhibited. In the present study, inhibition of Oatp-mediated uptake also reduced the partition of ATV in the liver, as reflected by the decrease in parent drug and metabolites detected in liver for the 5 and 10 µM RIF groups. However, the extent of metabolism remained unaltered as demonstrated by the similar OH ATV recovered in the entire system between control and 5 and 10 µM RIF treatment groups (Table 4), which we cannot explain at the present time. Although ATV liver retention was increased due to a combination of inhibition of enzyme and efflux transporter at 50 µM RIF, the perfusate AUC changes still suggest that uptake inhibition was in effect.
Inhibition of ATV hepatic uptake has implications beyond pharmacokinetics, because the liver is the site of action for ATV, as well as its two active metabolites. Considering that significant hydroxy metabolites are formed before reaching the liver due to intestinal CYP3A-mediated metabolism (Lennernas, 2003), a decrease in 3-hydroxy-3-methylglutaryl-CoA reductase inhibitory effect will probably occur under Oatp inhibition because hydroxy metabolites are substrates for Oatp and are equipotent as the parent drug.
A recent study examining the relationship between an OATP1B1 variant and ATV and pravastatin-induced rhabdomyolysis found that the OATP-C*15 mutant allele is significantly higher in patients who experienced statin-induced myopathy, suggesting the significance of OATP1B1 down-regulation to statin exposure (Morimoto et al., 2004). It has also been previously demonstrated that OATP/Oatp could be the major determinant in causing clinical drug-drug interactions between cerivastatin and cyclosporine (Shitara et al., 2003) and between bosentan and cyclosporine (Treiber et al., 2004). Our study further confirms the dominance of Oatp in mediating the interactions between ATV and the Oatp inhibitor RIF. RIF is a much weaker inhibitor of CYP3A compared with cyclosporine and therefore a better compound for differentiating uptake versus metabolism. Based on the results of the present study, we conclude that inhibition of hepatic uptake might be one of the major mechanisms for drug-drug interaction, particularly for metabolized compounds such as ATV. Future studies in our laboratory are examining the ATV-RIF interaction in whole animal and clinical studies.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
A portion of this data was presented at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, Baltimore, MD; 2004, November 7-11, and Gordon Research Conference on Drug Metabolism, Plymouth, NH; 2005, July 10-15.
Y.Y.L. was supported in part by an American Foundation for Pharmaceutical Education Predoctoral Fellowship.
ABBREVIATIONS: ATV, atorvastatin; MDCK, Madin-Darby canine kidney; MDR1, multidrug resistance gene; P-gp, P-glycoprotein; cMOAT, canalicular multiorganic anion transporter; MII, MDCKII; M-MDR1, MDCK-MDR1; MRP2/Mrp2, multidrug resistance-associated protein 2; HEK293, human embryonic kidney 293; OATP/Oatp, organic anion-transporting polypeptide; A, apical; B, basolateral; LC, liquid chromatography; MS, mass spectrometry; FBS, fetal bovine serum; IPRL, isolated perfused rat liver; PBS, phosphate-buffered saline; P450, cytochrome P450; AUC, area under the curve(s); 2-OH ATV, ortho-hydroxy atorvastatin; 4-OH ATV, para-hydroxy atorvastatin; HPLC, high-performance liquid chromatography; RIF, rifampicin; GG918 (GF120918), N-{4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamine.
Address correspondence to: Dr. Leslie Z. Benet, Professor, Department of Biopharmaceutical Sciences, 533 Parnassus, Room U-68, University of California, San Francisco, San Francisco, CA 94143-0446. E-mail: benet{at}itsa.ucsf.edu
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Black AE, Hayes RN, Roth BD, Woo P, and Woolf TF (1999) Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab Dispos 27: 916-923.
Cattori V, van Montfoort JE, Stieger B, Landmann L, Meijer DK, Winterhalter KH, Meier PJ, and Hagenbuch B (2001) Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflueg Arch Eur J Physiol 443: 188-195.[CrossRef][Medline]
Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, and Smolarek TA (2005) Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 33: 537-546.
Cui Y, Konig J, and Keppler D (2001) Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol 60: 934-943.
Cummins CL, Jacobsen W, Christians U, and Benet LZ (2004) CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther 308: 143-155.
Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27: 866-871.
Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude Elferink RP, Baas F, Schinkel AH, et al. (1998) Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Investig 101: 1310-1319.[Medline]
Fardel O, Lecureur V, Loyer P, and Guillouzo A (1995) Rifampicin enhances anticancer drug accumulation and activity in multidrug-resistant cells. Biochem Pharmacol 49: 1255-1260.[CrossRef][Medline]
Fattinger K, Cattori V, Hagenbuch B, Meier PJ, and Stieger B (2000) Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology 32: 82-86.[CrossRef][Medline]
Flanagan SD, Cummins CL, Susanto M, Liu X, Takahashi LH, and Benet LZ (2002) Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology 64: 126-134.[CrossRef][Medline]
Hochman JH, Pudvah N, Qiu J, Yamazaki M, Tang C, Lin JH, and Prueksaritanont T (2004) Interactions of human P-glycoprotein with simvastatin, simvastatin acid and atorvastatin. Pharm Res (NY) 21: 1686-1691.
Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, and Kirchgessner TG (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274: 37161-37168.
Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, and Christians U (2000) Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 28: 1369-1378.
Jacobson TA (2004) Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94: 1140-1146.[CrossRef][Medline]
Kakyo M, Unno M, Tokui T, Nakagomi R, Nishio T, Iwasashi H, Nakai D, Seki M, Suzuki M, Naitoh T, et al. (1999) Molecular characterization and functional regulation of a novel rat liver-specific organic anion transporter rlst-1. Gastroenterology 117: 770-775.[CrossRef][Medline]
Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, and Chiba K (2005) Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15: 513-522.[Medline]
Kantola T, Kivisto KT, and Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64: 58-65.[CrossRef][Medline]
Keppler D and Arias IM (1997) Hepatic canalicular membrane. Introduction: transport across the hepatocyte canalicular membrane. FASEB J 11: 15-18.[Medline]
Lam JL and Benet LZ (2004) Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 32: 1311-1316.
Lau YY, Wu CY, Okochi H, and Benet LZ (2004) Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther 308: 1040-1045.
Lennernas H (2003) Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42: 1141-1160.[CrossRef][Medline]
Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, and Stieger B (1997) Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26: 1667-1677.[Medline]
Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M, and Chiba K (2004) A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet 19: 453-455.[CrossRef][Medline]
Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, and Black DM (1995) Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15: 678-682.
Nezasa K, Higaki K, Takeuchi M, Nakano M, and Koike M (2003) Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica 33: 379-388.[Medline]
Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, and Willingham MC (1988) A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85: 4486-4490.
Sasaki M, Suzuki H, Aoki J, Ito K, Meier PJ, and Sugiyama Y (2004) Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion-transporting polypeptide 4 and multidrug resistance associated protein 2. Mol Pharmacol 66: 450-459.
Sasaki M, Suzuki H, Ito K, Abe T, and Sugiyama Y (2002) Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem 277: 6497-6503.
Shitara Y, Itoh T, Sato H, Li AP, and Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304: 610-616.
Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, and Sugiyama Y (2002) Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res (NY) 19: 147-153.
Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, and Schneck DW (2004) Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76: 167-177.[CrossRef][Medline]
Sun H, Huang Y, Frassetto L, and Benet LZ (2004) Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos 32: 1239-1246.
Tirona RG, Leake BF, Wolkoff AW, and Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304: 223-228.
Tokui T, Nakai D, Nakagomi R, Yawo H, Abe T, and Sugiyama Y (1999) Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharm Res (NY) 16: 904-908.
Treiber A, Schneiter R, Delahaye S, and Clozel M (2004) Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J Pharmacol Exp Ther 308: 1121-1129.
Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, and Fattinger K (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36: 164-172.[CrossRef][Medline]
Wu CY and Benet LZ (2003) Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine and GG918. Drug Metab Dispos 31: 1292-1295.
Wu X, Whitfield LR, and Stewart BH (2000) Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res (NY) 17: 209-215.
This article has been cited by other articles:
|
|
 |
|
  K. Grime, P. J. H. Webborn, and R. J. Riley Functional Consequences of Active Hepatic Uptake on Cytochrome P450 Inhibition in Rat and Human Hepatocytes Drug Metab. Dispos., August 1, 2008; 36(8): 1670 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Paine, A. J. Parker, P. Gardiner, P. J. H. Webborn, and R. J. Riley Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes Drug Metab. Dispos., July 1, 2008; 36(7): 1365 - 1374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Parker and J. B. Houston Rate-Limiting Steps in Hepatic Drug Clearance: Comparison of Hepatocellular Uptake and Metabolism with Microsomal Metabolism of Saquinavir, Nelfinavir, and Ritonavir Drug Metab. Dispos., July 1, 2008; 36(7): 1375 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Acharya, M. P. O'Connor, J. W. Polli, A. Ayrton, H. Ellens, and J. Bentz Kinetic Identification of Membrane Transporters That Assist P-glycoprotein-Mediated Transport of Digoxin and Loperamide through a Confluent Monolayer of MDCKII-hMDR1 Cells Drug Metab. Dispos., February 1, 2008; 36(2): 452 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Kalgutkar, B. Feng, H. T. Nguyen, K. S. Frederick, S. D. Campbell, H. L. Hatch, Y.-A. Bi, D. C. Kazolias, R. E. Davidson, R. J. Mireles, et al. Role of Transporters in the Disposition of the Selective Phosphodiesterase-4 Inhibitor (+)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic Acid in Rat and Human Drug Metab. Dispos., November 1, 2007; 35(11): 2111 - 2118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hallifax and J. B. Houston Saturable Uptake of Lipophilic Amine Drugs into Isolated Hepatocytes: Mechanisms and Consequences for Quantitative Clearance Prediction Drug Metab. Dispos., August 1, 2007; 35(8): 1325 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Lam, S. B. Shugarts, H. Okochi, and L. Z. Benet Elucidating the Effect of Final-Day Dosing of Rifampin in Induction Studies on Hepatic Drug Disposition and Metabolism J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 864 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Lam, H. Okochi, Y. Huang, and L. Z. Benet IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAY Drug Metab. Dispos., August 1, 2006; 34(8): 1336 - 1344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Y. Lau, H. Okochi, Y. Huang, and L. Z. Benet PHARMACOKINETICS OF ATORVASTATIN AND ITS HYDROXY METABOLITES IN RATS AND THE EFFECTS OF CONCOMITANT |
